Drug Profile
Trastuzumab glyco-optimised - Glycotope
Alternative Names: Glycooptimised TrastuzuMab-GEX; GT-Mab 7.3-GEX; TrasGEX; TrastuzuMab-GEXLatest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator Glycotope
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Gastric cancer
- No development reported Breast cancer
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for phase-I development in Gastric-cancer in Austria (IV, Infusion)
- 28 Mar 2018 No recent reports of development identified for phase-I development in Breast-cancer in Austria (IV, Infusion)
- 24 Jul 2017 Trastuzumab glyco-optimised - Glycotope is available for licensing as of 24 Jul 2017. http://www.glycotope.com/biopharmaceuticals-pipeline/ (Glycotope pipeline, July 2017)